Ensign Peak Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.6M | Sell |
6,645
-300
| -4% | -$72.4K | ﹤0.01% | 987 |
|
|
2025
Q1 | $1.69M | Sell |
6,945
-100
| -1% | -$24.4K | ﹤0.01% | 975 |
|
|
2024
Q4 | $2.31M | Hold |
7,045
| – | – | ﹤0.01% | 875 |
|
|
2024
Q3 | $2.36M | Buy |
7,045
+150
| +2% | +$50.2K | ﹤0.01% | 881 |
|
|
2024
Q2 | $1.88M | Hold |
6,895
| – | – | ﹤0.01% | 937 |
|
|
2024
Q1 | $2.38M | Sell |
6,895
-335
| -5% | -$116K | ﹤0.01% | 856 |
|
|
2023
Q4 | $2.33M | Hold |
7,230
| – | – | ﹤0.01% | 852 |
|
|
2023
Q3 | $2.59M | Buy |
7,230
+100
| +1% | +$35.8K | 0.01% | 755 |
|
|
2023
Q2 | $2.7M | Buy |
7,130
+300
| +4% | +$114K | 0.01% | 772 |
|
|
2023
Q1 | $3.27M | Buy |
6,830
+150
| +2% | +$71.9K | 0.01% | 680 |
|
|
2022
Q4 | $2.81M | Buy |
6,680
+1,627
| +32% | +$684K | 0.01% | 709 |
|
|
2022
Q3 | $2.11M | Buy |
5,053
+470
| +10% | +$196K | 0.01% | 765 |
|
|
2022
Q2 | $2.27M | Sell |
4,583
-65
| -1% | -$32.2K | 0.01% | 756 |
|
|
2022
Q1 | $2.62M | Sell |
4,648
-910
| -16% | -$513K | 0.01% | 784 |
|
|
2021
Q4 | $4.2M | Buy |
5,558
+3,427
| +161% | +$2.59M | 0.01% | 716 |
|
|
2021
Q3 | $1.59M | Sell |
2,131
-244
| -10% | -$182K | ﹤0.01% | 1235 |
|
|
2021
Q2 | $1.53M | Buy |
2,375
+335
| +16% | +$216K | ﹤0.01% | 1258 |
|
|
2021
Q1 | $1.17M | Sell |
2,040
-284
| -12% | -$162K | ﹤0.01% | 1371 |
|
|
2020
Q4 | $1.35M | Sell |
2,324
-877
| -27% | -$511K | ﹤0.01% | 1267 |
|
|
2020
Q3 | $1.65M | Sell |
3,201
-13,867
| -81% | -$7.15M | ﹤0.01% | 1071 |
|
|
2020
Q2 | $7.71M | Hold |
17,068
| – | – | 0.02% | 485 |
|
|
2020
Q1 | $5.98M | Hold |
17,068
| – | – | 0.02% | 466 |
|
|
2019
Q4 | $6.32M | Buy |
+17,068
| New | +$6.32M | 0.02% | 576 |
|